Digestive Health Newsletter

Colon Cancer Screening

Douglas K. Rex, MD

Volume 11, 
July 01, 2008

by Douglas K. Rex, MD

Douglas Rex Douglas K. Rex, MD is Chancellor's Professor and Professor of Medicine at Indiana University School of Medicine and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude and with highest distinction from Indiana University School of Medicine. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as and Department of Medicine's Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital. His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and those of the Gastroenterology Consortium. He has served as the ACG representative to the National Colorectal Cancer Round Table, and from 2000-2006 was the chairman of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors, Secretary, and Treasurer and is a Past President of the ACG.

Table of Contents

Introduction

In the United States, colorectal cancer (which is sometimes simply called "colon cancer") is the second leading cause of death from cancer and third most common cancer diagnosed in men and women1. The good news is that, if diagnosed while still confined to the colon, the five–year survival rate for patients with colon cancer is 90%. Early detection is critical, since the survival rate drops to 68% if the cancer has spread to the lymph nodes and to 10% if the cancer has metastasized to other parts of the body. Although there is no question that early detection is critical, less than half of Americans aged 50 or older undergo routine screening2.

Back to Top

What is colon cancer?

Healthy cells grow and divide to form new cells as your body needs them. Cancerous cells reproduce when your body does not need them, forming a mass of cells called a tumor, which can be benign or malignant. In colon cancer, tumors typically arise from the cells that line the colon (also known as the large intestine) and/or the rectum.

Back to Top

Who is at risk for colon cancer?

Colon cancer is most common in people aged 50 years or older. Most colon cancers begin in colorectal polyps (growths that protrude from the inner wall of the colon and/or rectum). The following photos show a normal colon and a colon with a polyp. Polyps are benign, but can be considered pre–cancerous, especially those determined by a pathologist to be adenomas. Finally, if you have inflammatory bowel disease (IBD) and/or a family history of colon cancer, you are also at increased risk. (For more information about IBD and colon cancer, refer to the IBD and Cancer newsletter.)

Normal Colon This photo shows the lining of a normal colon.

Colon with polyps This photo shows a colon with a polyp.

Keep in mind that lifestyle (for example, smoking, obesity, and lack of exercise) plays an important role in which at–risk individuals actually develop colon cancer. However, about 80% of all colon cancer cases occur in people with no family history of colon cancer and without IBD3.

Back to Top

How is colon cancer detected?

In the early stages of colon cancer, some people may experience changes in bowel habits; blood in stool; unexplained weight loss, fatigue, or stomach pain; and/or bloating and cramps. However, others may have no warning symptoms. Screening tests can help your doctor find and remove polyps or cancer before symptoms occur. This is critical, since the treatment of colon cancer is more likely to be effective if the disease is found early. Adults without risk factors should have their first colon cancer screening at age 50, and adults with risk factors should undergo more frequent screening beginning at an earlier age.

Back to Top

What screening tests are available?

There are two general types of colon cancer screening tests: fecal tests and partial or full structural exams. Fecal tests are used to identify colon cancer and may also detect some premalignant adenomatous polyps. They include the guaiac fecal occult blood test (gFOBT), the fecal immunochemical test (FIT), and the stool DNA (sDNA) test. Partial or full structural exams are used to detect both cancer and premalignant adenomatous polyps. They include colonoscopy, sigmoidoscopy, double contrast barium enema, and computerized tomographic (CT) colonography (also called virtual colonoscopy).

Fecal tests

Partial/full structural exams

Back to Top

Does health insurance cover screening?

Because there is currently no federal legislation requiring insurance companies to pay for preventive screening, coverage varies and you must check with your insurance provider to determine your benefits.

Medicare recipients are entitled to colonoscopy screenings every ten years, sigmoidoscopy and double–contrast barium enema screenings every five years, and annual fecal occult blood tests, whereas Medicaid coverage varies by state.

The Colorectal Cancer Legislation Report Card is an annual assessment of each state's preventive screening legislation. It is supported by a coalition that includes the American Cancer Society Cancer Action Network, American College of Gastroenterology, American Gastroenterological Association, American Society of Colon and Rectal Surgeons, American Society of Gastrointestinal Endoscopy, and many other organizations. According to the 2008 report, more than half of the U.S. population benefits from state laws requiring insurance providers to cover cost of colon cancer screening tests, but 26 states still do not assure screening coverage. If that is the case in your state, urge your elected officials to support such legislation.

Free or low–cost screening is available in a number of areas, including the following locations:

Suffolk County, NY (631–444–7644) Baltimore, MD (410–887–3456 or 1–866–632–6566)
King, Clallam, and Jefferson counties, WA (1–800–756–5437)
Nebraska (1–800–532–2227)
St. Louis, MO (314–879–6392)

To locate free or low–cost screening elsewhere in United States, call 1–800–4–CANCER or 1–800–ACS–2345.

Back to Top

Questions to ask your doctor

When you meet with your physician to discuss colon cancer screening, it may help to have a list of questions to help guide the discussion. The following are some suggestions to help you get started.

 

Click here to print out and take to your doctor.

Back to Top

Conclusion

According to the Centers for Disease Control, four out of every ten people who should be screened for colon cancer are not being tested within the suggested timeframe4. Remember that colon cancer screening gives you the power to stop colon cancer before it starts. More than half of all instances of colon cancer could be prevented if everyone age 50 and older was screened regularly5. If you are at least 50 years old or have any of the risk factors described in this newsletter, call your physician and schedule an appointment.


  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. Epub 2008 Feb 20.
  2. Centers for Disease Control and Prevention. Colorectal (colon) cancer screening rates. Available at: www.cdc.gov/cancer/colorectal/statistics/screening_rates.htm. Accessed June 16, 2008.
  3. Torneo CA, Colditz GA, Willett W, et al. Harvard report on cancer prevention. Volume 3: prevention of colon cancer in the United States. Cancer Causes Control. 1999;10:167-180.
  4. CDC. Use of colorectal cancer tests -- U.S., 2002, 2004, and 2006. MMWR 2008; 57(10): 253-58.
  5. Torneo CA, Colditz GA, Willett W, et al. Harvard report on cancer prevention. Volume 3: prevention of colon cancer in the United States. Cancer Causes Control. 1999;10:167-180.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter